Antihypertensive agents in hemodialysis patients: A current perspective

Seminars in Dialysis

Volumn 23, Issue 3, 2010, Pages 290-297

  Inrig, Jula K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; HUMAN; METABOLISM; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVIEW; TREATMENT OUTCOME; COMPLICATION; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION, RENAL; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 77955137058     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2009.00697.x     Document Type: Review

References (69)

1. Agarwal R, Nissenson AR, Battle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003, 115:291-297.
2. Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, Salvador M, Chamontin B. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 2000, 57:2485-2491.
3. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000, 58:2147-2154.
4. Takeda A, Toda T, Fujii T, Shinohara S, Sasaki S, Matsui N. Discordance of influence of hypertension on mortality and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2005, 45:112-118.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996, 49:1379-1385.
6. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001, 12:2759-2767.
7. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension 2009, 53:860-866.
8. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, Gallagher M, Roberts MA, Cass A, Neal B, Perkovic V. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009, 373:1009-1015.
9. Inrig JK, Patel UD, Gillespie BS, Hasselblad V, Himmelfarb J, Reddan D, Lindsay RM, Winchester JF, Stivelman J, Toto R, Szczech LA. Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients. Am J Kidney Dis 2007, 50:108-118.
10. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial. Hypertension 2009, 53:500-507.
11. Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, Yoshizawa M, Furukawa T, Takenaka T, Saruta T. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 2005, 45:866-874.
12. Matsumoto N, Ishimitsu T, Okamura A, Seta H, Takahashi M, Matsuoka H. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res 2006, 29:253-260.
13. Takahashi A, Takase H, Toriyama T, Sugiura T, Kurita Y, Ueda R, Dohi Y. Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis-a randomized study. Nephrol Dial Transplant 2006, 21:2507-2512.
14. Suzuki H, Kanno Y, Sugahara S, Ikeda N, Shoda J, Takenaka T, Inoue T, Araki R. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008, 52:501-506.
15. K/DOQI Clinical Practice Guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005, 45(Suppl. 4):S49-S59. S69-S75
16. Agarwal R, Lewis R, Davis JL, Becker B. Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses. Am J Kidney Dis 2001, 38:1245-1250.
17. Zannad F, Kessler M, Lehert P, Grunfeld JP, Thuilliez C, Leizorovicz A, Lechat P. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 2006, 70:1318-1324.
18. Han SW, Won YW, Yi JH, Kim HJ. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant 2007, 22:1150-1155.
19. Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 2002, 112:110-114.
20. Garthwaite E, Bhandari S. The effects of angiotensin converting enzyme inhibitors on potassium homeostasis in dialysis patients with and without residual renal function. Artif Organs 2009, 33:641-647.
21. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008, 148:16-29.
22. Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 1995, 10:2107-2109.
23. Parnes EL, Shapiro WB. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int 1991, 40:1148-1152.
24. Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones CA, Bloembergen WE. Predictors of loss of residual renal function among new dialysis patients. J Am Soc Nephrol 2000, 11:556-564.
25. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002, 40:1023-1029.
26. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003, 42:201-208.
27. McCullough PA, Sandberg KR, Yee J, Hudson MP. Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst 2002, 3:188-191.
28. Pun PH, Lehrich RW, Smith SR, Middleton JP. Predictors of survival after cardiac arrest in outpatient hemodialysis clinics. Clin J Am Soc Nephrol 2007, 2:491-500.
29. Inrig JK, Oddone EZ, Hasselblad V, Gillespie B, Patel UD, Reddan D, Toto R, Himmelfarb J, Winchester JF, Stivelman J, Lindsay RM, Szczech LA. Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients. Kidney Int 2007, 71:454-461.
30. Inrig JK. Intradialytic hypertension, a less recognized cardiovascular complication of hemodialysis. Am J Kidney Dis 2009, 10.1053/j.ajkd.2009.08.013, doi
31. Tepel M, van der Giet M, Zidek W. Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes. Kidney Blood Press Res 2001, 24:71-74.
32. Suzuki H, Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 2004, 8:320-327.
33. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559.
34. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
35. Saudan P, Mach F, Perneger T, Schnetzler B, Stoermann C, Fumeaux Z, Rossier M, Martin P-Y. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003, 18:2359-2363.
36. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003, 18:2364-2368.
37. Gross E, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005, 46:94-101.
38. Matsumoto Y, Kageyama S, Yakushigawa T, Arihara K, Sugiyama T, Mori Y, Sugiyama H, Ohmura H. Long-term low dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 2009, 114:32-38. Shio N
39. Parving H-H, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358:2433-2446.
40. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. Kidney Int 1999, 55:1528-1535.
41. Nowicki M, Miszczak-Kuban J. Nonselective Beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients. Nephron 2002, 91:222-227.
42. Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 1990, 37:793-798.
43. Abbott KC, Trespalacios FC, Agodoa LY, Taylor AJ, Bakris GL. Beta-blocker use in long-term dialysis patients: association with hospitalized heart failure and mortality. Arch Intern Med 2004, 164:2465-2471.
44. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in US hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002, 62:1784-1790.
45. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004, 364:1684-1689.
46. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003, 41:1438-1444.
47. Brophy JM, Joseph L, Rouleau JL. Beta-Blockers in Congestive Heart Failure. Ann Inter Med 2001, 134:550-560.
48. Nowicki M, Szewczyk-Seifert G, Klimek D, Kokot F. Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients. Clin Nephrol 2002, 57:352-358.
49. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A. Dilated cardiomyopathy in dialysis patients--beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 2001, 37:407-411.
50. London GM, Marchais SJ, Guerin AP, Metivier F, Safar ME, Fabiani F, Froment L. Salt and water retention and calcium blockade in uremia. Circulation 1990, 82:105-113.
51. Tepel M, Hopfenmueller W, Scholze A, Maier A, Zidek W. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant 2008, 23:3605-3612.
52. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002, 61:2157-2164.
53. Tepel M, Giet MV, Park A, Zidek W. Association of calcium channel blockers and mortality in haemodialysis patients. Clin Sci (Lond) 2002, 103:511-515.
54. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994, 90:2786-2796.
55. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000, 283:1967-1975.
56. Ross EA, Pittman TB, Koo LC. Strategy for the treatment of noncompliant hypertensive hemodialysis patients. Int J Artif Organs 2002, 25:1061-1065.
57. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
58. Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, Cruz JM, Akiba T, Kurokawa K, Ramirez S, Young EW. Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis 2007, 49:426-431.
59. Prasad VS, Palaniswamy C, Frishman WH. Endothelin as a clinical target in the treatment of systemic hypertension. Cardiol Rev 2009, 17:181-191.
60. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation 1991, 84:1457-1468.
61. Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type. Br J Pharmacol 1995, 114:1110-1116.
62. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338:784-790.
63. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002, 15:583-589.
64. Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007, 9:760-769.
65. Brochu E, Lacasse-M S, Lariviere R, Kingma I, Grose JH, Lebel M. Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 1999, 10:1440-1446.
66. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002, 90:256-261.
67. Kanno Y, Kaneko K, Kaneko M, Kotaki S, Mimura T, Takane H, Suzuki H. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol 2004, 43:380-386.
68. Johnson CA. Dialysis of drugs. 2008, http://www.ckdinsights.com/downloads/DialysisDrugs2008.pdf, Available at:
69. UpToDate 2010, Rose BD. UpToDate Drug Information, ed, Waltham, MA, UpToDate